Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Metabasis Therapeutics has completed the four protocol-defined dose groups in its Phase Ib multiple-dose clinical trial evaluating the safety and tolerability of MB07811, its novel product candidate for the treatment of hyperlipidemia.
Subscribe to our email newsletter
Preliminary results from this ongoing trial indicate that MB07811 is safe and well tolerated at the doses studied, and based on these findings, the company plans to explore the safety and tolerability of higher doses. In addition, the company announced that the preliminary results from this trial suggest that MB07811 reduced fasting low-density lipoprotein (LDL) cholesterol levels, as well as fasting triglyceride (TG) levels.
The trial was designed to study safety and tolerability of four doses of MB07811 (0.25mg, 1mg, 2.5mg and 5mg). Because these doses were found to be safe and well tolerated, Metabasis plans to evaluate a dose of 10mg and to escalate to higher doses if the 10mg dose proves to be safe and well tolerated. The preliminary results of the trial also suggest that MB07811 reduced LDL-cholesterol and TG levels following administration of MB07811 for 14 days.